



Yang, X., Beroske, L. P., Kemmink, J., Rijkers, D. T.S. and Liskamp, R. M.J. (2017) Synthesis of bicyclic tripeptides inspired by the ABC-ring system of vancomycin through ruthenium-based cyclization chemistries. *Tetrahedron Letters*, 58(48), pp. 4542-4546. (doi:[10.1016/j.tetlet.2017.10.046](https://doi.org/10.1016/j.tetlet.2017.10.046))

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/151790/>

Deposited on: 19 December 2017

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>


Graphical Abstract

To create your abstract, type over the instructions in the template box below.
Fonts or abstract dimensions should not be changed or altered.

Synthesis of bicyclic tripeptides inspired by the ABC-ring system of vancomycin through ruthenium-based cyclization chemistries

Xin Yang, Lucas P. Beroske, Johan Kemmink, Dirk T. S. Rijkers, and Rob M. J. Liskamp

Leave this area blank for abstract info.



Synthesis of bicyclic tripeptides inspired by the ABC-ring system of vancomycin through ruthenium-based cyclization chemistries

Xin Yang^a, Lucas P. Beroske^a, Johan Kemmink^{a,†}, Dirk T.S. Rijkers^{a,*} and Rob M. J. Liskamp^{b,*}

^aDivision of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands

^bSchool of Chemistry, University of Glasgow, Joseph Black Building, University Avenue, Glasgow, G12 8QQ, United Kingdom

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

Macrocycles

Peptides

Peptidomimetics

Ring-closing metathesis

Ru-based Azide-Alkyne Cycloaddition

ABSTRACT

The synthesis of a bicyclic tripeptide that mimics the ABC ring system of vancomycin is described by using a ring closing metathesis (RCM) – peptide coupling – ruthenium-catalyzed azide-alkyne cycloaddition (RuAAC) strategy.

1. Introduction

Cyclic peptides are increasingly important and serve as relevant lead structures and bioactive molecules in medicinal chemistry and drug design since they offer a plethora of biological activities and especially interesting for modulation of protein-protein interactions.¹ Their (total) synthesis, however, is still a highly challenging task and the development of novel and efficient cyclization approaches is an active field of research.^{1f} Within this class, multicyclic as well as side chain knotted cyclic peptides, like the conotoxins and cyclotides,² lantibiotics,³ and glycopeptide antibiotics,⁴ are of special interest since they combine extreme potency with shape persistent folding of the peptide backbone. The most classical and outstanding example of the effects of macrocyclization and side chain knotting is found in the heptapeptide vancomycin.⁵ These lead to an almost absolute control of shape and folding of this glycopeptide antibiotic and allows for a very strong binding of the rather flexible natural target ~Lys-D-Ala-D-Ala-OH.⁶

Over the years we have been inspired by cyclized peptides such as vancomycin as well as nisin and we have explored alternative approaches for peptide cyclization, among others, Sonogashira cross-coupling,⁷ ring closing metathesis⁸ and Cu⁺ as well as Ru²⁺ catalyzed azide-alkyne cycloadditions,⁹ to obtain

highly constrained side chain to side chain knotted peptides. Previously, we have shown that alkyne-, alkene- and triazole-tethered cyclic tri-, hexa- and heptapeptides could be synthesized that mimic vancomycin by binding ~Lys-D-Ala-D-Ala-OH and ~Lys-D-Ala-D-Lac-OH. To increase the rigidity of these mimics further, we were looking for complementary cyclization approaches for introducing an additional cyclic constraint to control the sequence of cyclization and thereby the folding topology of the peptide backbone. So far, most vancomycin mimics, including our own, have focused mainly on the CDE-ring system.¹⁰ However, the ABC-ring system probably provides the additional needed rigidity in the form of a lid, making vancomycin more of a clam to hold ~Lys-D-Ala-D-Ala-OH more permanently by reducing the off-rate. Herein, we describe our efforts towards effective mimicry of the ABC-ring system,^{10h, 11, 12} which ultimately combined with DE-mimicry should lead to potent vancomycin mimics.

2. Results and discussion

Previously we have reported the synthesis of triazole-containing vancomycin mimics like **14** (Figure 1).^{9b} Despite their bicyclic framework these structures are still relatively flexible, since mimics as **14** do bind Ac-Lys(Ac)-D-Ala-D-Ala-OH albeit

* Corresponding author. Tel.: +31 (0)6 2026 0572; fax: +31 (0)30 253 6655; e-mail: D.T.S.Rijkers@uu.nl

* Corresponding author. Tel.: +44 (0)141 330 5168; fax: +44 (0)141 330 6867; e-mail: Robert.Liskamp@glasgow.ac.uk

† Present address: University of Groningen, Faculty of Mathematics and Natural Sciences, Stratingh Institute, Nijenborgh 4, 9747 AG Groningen, The Netherlands

with a lower affinity than vancomycin as judged by isothermal microcalorimetry (ITC). In order to include the AB-ring system,¹¹ we wished to apply RCM, which we and others have done successfully on several occasions.¹³ This led to the target bicyclic tripeptide **10**. Retrosynthesis showed that bicycle **10** might be accessible through two consecutive macrocyclization steps starting from **12** (Figure 1). Since the preferred order of the macrocyclization steps, by RCM or RuAAC,¹⁴ was not known (*vide infra*), precursor dipeptide **7** was proposed, to optimize RCM in the presence of an azide moiety (Figure 1).





Figure 1. Design of vancomycin mimics.

TMS-protected alkyne **3** was conveniently accessible from commercially available 4-hydroxy-D-phenylglycine (Scheme 1). After protection of the amine group and conversion of the phenolic hydroxy group to a methyl ether and preparation of the methyl ester, amino acid derivative **1** was subjected to iodination, according to Nicolaou et al.,¹⁵ to give mono-iodo compound **2** in high yield (90%). After saponification of the methyl ester, the alkyne was installed by a Pd-catalyzed Sonogashira cross-coupling reaction to give protected phenylglycine building block **3** in an acceptable yield of 57%.¹⁶




Scheme 1. Synthesis of phenylglycine building block **3**.


The synthesis of the required RCM-precursor **7** is shown in Scheme 2. To this end 2-allylaniline **4** was obtained by a Claisen rearrangement according to Brucelle and Renaud.¹⁷ In a first attempt to couple aniline **4** to azido acid **5**,¹⁸ BOP/DIPEA as coupling reagent did not afford anilide **6**. Therefore, DCC in pyridine was used to form the anilide **6** in 54% yield since this combination of coupling reagent/solvent was effective in the coupling of the poor nucleophile 4-nitroaniline with amino acids.¹⁹ After deprotection of anilide **6** by treatment with TFA, Boc-D-Alg-OH was coupled by BOP/DIPEA, and bisalkene dipeptide **7** was obtained in 92% yield over two steps.

As RCM precursor peptide **7** contained an azide moiety, the first²⁰ and second²¹ generation Grubbs catalysts could not be used

since the tricyclohexylphosphine ligands would likely reduce the azide into an amine via a Staudinger reduction.²² Therefore, the second generation Hoveyda-Grubbs catalyst²³ was used in refluxing CH_2Cl_2 and macrocyclic peptide **8** was isolated in 55% yield as a mixture of the *E/Z* diastereoisomers, as shown in Scheme 3 (**8a** (*Z*):**8b** (*E*) = 1:2.3). After Boc removal both diastereoisomers **8ab** could be separated by preparative HPLC and characterized as well as identified by NMR and LC-(HR)MS.



Scheme 2. Synthesis of RCM precursor dipeptide **7**.




Scheme 3. RCM-coupling-RuAAC strategy for the synthesis of bicyclic tripeptide **10**.

In its protected form, both diastereoisomers (R_t 32.97 and 33.36 min) of macrocycle **8** could not be separated as is shown in Figure SI-18. However, when an aliquot of **8** was treated with TFA to remove the Boc functionality this resulted in a base line separation of both diastereoisomers **8ab** (R_t 22.24 and 22.98 min, Figure SI-19). The ^1H NMR spectrum of diastereoisomer **8a** gave broad peaks at 25°C, fortunately at higher temperature, peak splitting was observed and at 80°C a well-defined *J* coupling of the olefinic protons could be derived (Figure SI-11). This value, ~8 Hz, corresponded to the *Z*-configuration of the double bond. The proton spectrum of diastereoisomer **8b** had resulted already at 25°C in a well-defined *J* coupling of ~13 Hz of the alkene bond indicating an *E*-geometry of **8b** (Figure SI-12).²⁴

Thus, macrocycle **8** was treated with TFA and the free α -amine was coupled to alkyne derivative **3** in the presence of BOP/DIPEA to afford the protected click precursor **9** in 54% overall yield (Scheme 3). Then, tripeptide **9** was treated with TBAF to remove the TMS functionality and the unprotected alkyne was isolated in 95% yield after column chromatography and subjected to RuAAC in THF/MeOH as solvent system at

80°C under microwave irradiation in the presence of 10 mol% [Cp**RuCl*]₄ as catalyst. Bicyclic tripeptide **10** was isolated in 22% yield after column chromatography as a mixture of *E/Z* diastereoisomers. Heating at 80°C under microwave irradiation in the absence of [Cp**RuCl*]₄ did not lead to any conversion. To improve the yield of cyclization, lower and higher catalyst loadings (5 and 15 mol%, respectively) were used and turned out to be ineffective since incomplete conversion of starting material (at 5 mol%) or extensive formation of baseline compounds (at 15 mol%) were observed instead. As a control experiment, the unprotected alkyne was also subjected to regular CuAAC²⁵ in the presence of either CuI or [Cu(CH₃CN)₄]*PF*₆ as the Cu⁺ species, and these reaction conditions did not lead to the formation of bicyclic tripeptide **10**. This experiment showed that a 1,5-triazole moiety with a curved geometry was essential for ring closure since the more linear geometry of the 1,4-triazole was clearly incompatible with the topology of the bicyclic framework of tripeptide **10**. Similar to macrocycle **8**, the individual diastereoisomers of bicyclic tripeptide **11** (*Z*-**11a** and *E*-**11b**, respectively) could be obtained after Boc removal of **10** and purification by preparative HPLC. It is interesting to note that the *Z:E* ratio during the conversion of **8ab** into **11ab** shifted from 1:2.3 to 2:1, an indication that the *Z*-geometry of the alkene was favored in the bicyclic tripeptide topology.

Since bicyclic tripeptide **11** can be used as a versatile building block in the synthesis of tricyclic heptapeptides to mimic the side chain to side chain connectivity pattern of vancomycin, hydrogenation of the double bond to an alkane bridge would be desirable to obtain a single isomer instead of an *E/Z* mixture of diastereoisomers. Therefore, several hydrogenation conditions in the presence of Pd/C, Raney Ni, and Pd(OH)₂ were investigated, unfortunately all were unsuccessful.



Scheme 4. Alternative RCM-coupling-RuAAC strategies for the synthesis of bicyclic tripeptide **10**.

Two reverse reaction sequences to arrive at the desired bicyclic tripeptide **10** were also investigated, both started from linear dipeptide **7** (Scheme 4). As the first step, Boc-protected **7** was treated with TFA and the resulting amine was coupled to alkyne derivative **3** in the presence of BOP/DIPEA to afford tripeptide **12** in 69% yield after purification by column chromatography. RCM of precursor peptide **12** in the presence of Hoveyda-Grubbs 2G catalyst in CH₂Cl₂ or 1,2-dichloroethane did not result in the formation of alkene-bridged macrocycle **9**. The progress of the reaction was monitored by LCMS, although starting material was gone, the desired bicyclic peptide **9** could not be observed. In hindsight, it was assumed that the desired ene-ene RCM pathway was possibly overrun by the thermodynamically favored ene-yne reactivity to yield 2-silyl-

substituted 1,3-dienes, which were not identified.²⁶ Alternatively, TMS-protected precursor peptide **12** was treated with TBAF and subsequently subjected to RuAAC to install the triazole moiety as the cyclic constraint. Via this route, macrocycle **13** was obtained in a better 41% yield than in the above preparation of **10** (Scheme 3). Unfortunately, RCM of **13** did not result in the successful isolation of bicyclic tripeptide **10**. TLC analysis indicated that conversion of the starting compound was not complete and some baseline material was present and the formation of bicyclic tripeptide **10** could not be observed by LCMS.




Figure 2. Superimposition of balhimycin (in red) with bicyclic tripeptide **11a** (left) and **11b** (right), respectively. The carbon atoms αC^1 , αC^2 , αC^3 , arom- C^4 , triazole- C^5 , N^6 , benzylic- C^7 have been used as fixed coordinates for superimposition.

Table 1. The binding affinity as measured using ITC.

| compound | ligand | K_a (M ⁻¹) ^a |
|------------|---------------------------|---------------------------------------|
| VM | Ac-Lys(Ac)-D-Ala-D-Ala-OH | (3.95±0.41)×10 ⁵ |
| VM | Ac-Lys(Ac)-D-Ala-D-Lac-OH | (2.38±0.23)×10 ³ |
| 11a | Ac-Lys(Ac)-D-Ala-D-Ala-OH | (2.35±0.36)×10 ³ |
| 11a | Ac-Lys(Ac)-D-Ala-D-Lac-OH | (2.17±0.30)×10 ³ |
| 11b | Ac-Lys(Ac)-D-Ala-D-Ala-OH | (4.06±0.84)×10 ³ |
| 11b | Ac-Lys(Ac)-D-Ala-D-Lac-OH | (1.21±0.86)×10 ³ |

^aMeasured in a Na-citrate/citric acid buffer (0.02 M, pH 5.1), VM: vancomycin.

The structures of bicyclic tripeptides **11a** (as the *Z*-diastereoisomer) and **11b** (as the *E*-diastereoisomer) were energy minimized using the simulated annealing protocol employing the AMBER99 force field using the YASARA Structure 10.5.2.1 software package.²⁷ The peptides were superimposed with the left half of the vancomycin-related balhimycin antibiotic comprising the ABC-ring system.²⁸ An RMSD of 0.76 and 0.58 Å over seven atoms was calculated (see Scheme 3 for atom numbering) of the superimpositions of **11a** and **11b**, respectively. To evaluate if this structural resemblance correlates with binding affinity toward Ac-Lys(Ac)-D-Ala-D-Ala-OH and Ac-Lys(Ac)-D-Ala-D-Lac-OH, isothermal microcalorimetry (ITC) was performed, as shown in Table 1.^{29, 30} Based on these data, mimics **11a** and **11b** still bind Ac-Lys(Ac)-D-Ala-D-Ala-OH appreciably, considering that a large part of the 'clam' is missing, albeit at least 100-fold less compared to vancomycin. Bicycle **11b** is somewhat more active than **11a**, while binding toward Ac-Lys(Ac)-D-Ala-D-Lac-OH was comparable for all three receptor molecules. This was in line with the MIC-values obtained from a growth inhibition assay³¹ of *Staphylococcus aureus* ATCC 49320 strain, since 300 µg/mL (**11b**), >300 µg/mL (**11a**) and 2 µg/mL (VM) were found, respectively. Although a reasonable structural resemblance was found, not unexpectedly, for efficient binding (and activity) some extra factors need to be addressed like proper alignment of

hydrogen bonding and further rigidification, possibly in attempts to combine the ABC and CDE-ring systems.^{9b}

3. Conclusion

In conclusion, bicyclic tripeptide **10** as a mimic of the ABC-ring system was successfully synthesized starting from precursor dipeptide **7** following an RCM-coupling-RuAAC strategy. Mimics of this part of the vancomycin structure are less explored as only a single hydrogen bond contributes to the binding of Ac-Lys(Ac)-D-Ala-D-Ala-OH via the carbonyl oxygen of the lysine residue. The mixture of double bond isomers could be separated in each individual *E/Z* diastereoisomer as the free amine by HPLC as judged by NMR and LC-MS. Bicyclic tripeptide **10** is an important building block to ultimately arrive at a series of tricyclic heptapeptides for possible effective mimicry of vancomycin in which ruthenium-based cyclization approaches will be used to control the topology and rigidity of the peptide backbone.

Acknowledgments

This research was supported by the China Scholarship Council (CSC) awarded to X.Y. We thank Javier Sastre Torano for performing the HRMS analyses and Hao Zhang for his help with the modeling experiments.

References and notes

- (a) Gilon, C.; Halle, D.; Chorev, M.; Selinger, Z.; Byk, G. *Biopolymers* **1991**, *31*, 745–750. (b) Wessjohann, L. A.; Ruijter, E.; Garcia-Rivera, D.; Brandt, W. *Mol. Divers.* **2005**, *9*, 171–186. (c) Katsara, M.; Tselios, T.; Deraos, S.; Deraos, G.; Matsoukas, M.-T.; Lazoura, E.; Matsoukas, J.; Apostolopoulos, V. *Curr. Med. Chem.* **2006**, *13*, 2221–2232. (d) Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. *Nat. Rev. Drug Discovery* **2008**, *7*, 608–624. (e) Marsault, E.; Peterson, M. L. *J. Med. Chem.* **2011**, *54*, 1961–2004. (f) White, C. J.; Yudin A. K. *Nat. Chem.* **2011**, *3*, 509–524.
- (a) Janes, R. W. *Curr. Opin. Pharmacol.* **2005**, *5*, 280–292. (b) de Veer, S. J.; Weidmann, J.; Craik, D. J. *Acc. Chem. Res.* **2017**, *50*, 1557–1565.
- Chatterjee, C.; Paul, M.; Xie, L.; van der Donk, W. A. *Chem. Rev.* **2005**, *105*, 633–684.
- Binda, E.; Marinelli, F.; Marcone, G. L. *Antibiotics* **2014**, *3*, 572–594.
- (a) James, R. C.; Pierce, J. G.; Okano, A.; Boger, D. L. *ACS Chem. Biol.* **2012**, *7*, 797–804. (b) Okano, A.; Isley, N. A.; Boger, D. L. *Chem. Rev.* **2017**, 10.1031/acs.chemrev.6b00820.
- (a) Williams, D. H.; Bardsley, B. *Angew. Chem., Int. Ed.* **1999**, *38*, 1172–1193. (b) Nicolaou, K. C.; Mitchell, H. J.; Jain, N. F.; Winessinger, N.; Hughes, R.; Bando, T. *Angew. Chem., Int. Ed.* **1999**, *38*, 240–244.
- ten Brink, H. T.; Rijkers, D. T. S.; Liskamp, R. M. J. *J. Org. Chem.* **2006**, *71*, 1817–1824.
- ten Brink, H. T.; Rijkers, D. T. S.; Kemmink, J.; Hilbers, H. W.; Liskamp, R. M. J. *Org. Biomol. Chem.* **2004**, *2*, 2658–2663.
- (a) Zhang, J.; Kemmink, J.; Rijkers, D. T. S.; Liskamp, R. M. J. *Org. Lett.* **2011**, *13*, 3438–3441. (b) Zhang, J.; Kemmink, J.; Rijkers, D. T. S.; Liskamp, R. M. J. *Chem. Commun.* **2013**, *49*, 4498–4500.
- (a) Pant, N.; Hamilton, A. D. *J. Am. Chem. Soc.* **1988**, *110*, 2002–2003. (b) Evans, D. A.; Ellman, J. A.; DeVries K. M. *J. Am. Chem. Soc.* **1989**, *111*, 8912–8914. (c) Boger, D. L.; Borzilleri, R. M.; Nukui, S. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 3091–3096. (d) Bois-Choussy, M.; Neuville, L.; Beugelmans, R.; Zhu, J. *J. Org. Chem.* **1996**, *61*, 9309–9322. (e) Boger, D. L.; Borzilleri, R. M.; Nukui, S.; Beresis, R. T. *J. Org. Chem.* **1997**, *62*, 4721–4736. (f) Xu, R.; Greiveldinger, G.; Marenus, L. E.; Cooper, A.; Ellman, J. A. *J. Am. Chem. Soc.* **1999**, *121*, 4898–4899. (g) Boger, D. L.; Castle, S. L.; Miyazaki, S.; Wu, J. H.; Beresis, R. T.; Loiseleur, O. *J. Org. Chem.* **1999**, *64*, 70–80. (h) Boger, D. L.; Miyazaki, S.; Kim, S. H.; Wu, J. H.; Castle, S. L.; Loiseleur, O.; Jin, Q. *J. Am. Chem. Soc.* **1999**, *121*, 10004–10011. (i) Arnusch, C. J.; Pieters, R. J. *Eur. J. Org. Chem.* **2003**, 3131–3138. (j) Pearson, A. J.; Ciurea D. V. *J. Org. Chem.* **2008**, *73*, 760–763.
- Although bicycle **10** represents the ACD-ring system of vancomycin we call this fragment an ABC-ring mimic to stress the fact that **10** represents the C-terminal part of vancomycin.
- (a) Evans, D. A.; Dinsmore, C. J. *Tetrahedron Lett.* **1993**, *34*, 6029–6032. (b) Evans, D. A.; Dinsmore, C. J.; Evrard, D. A.; DeVries, K. M. *J. Am. Chem. Soc.* **1993**, *115*, 6426–6427.
- (a) Miller, S. J.; Blackwell, H. E.; Grubbs, R. H. *J. Am. Chem. Soc.* **1996**, *118*, 9606–9614. (b) Gradillas, A.; Pérez-Castells, J. *Angew. Chem., Int. Ed.* **2006**, *45*, 6086–6101. (c) Brik, A. *Adv. Synth. Catal.* **2008**, *350*, 1161–1675. (d) Gleeson, E. C.; Jackson, W. R.; Robinson, A. J. *Tetrahedron Lett.* **2016**, *57*, 4325–4333. (e) Rijkers, D. T. S. *Top. Heterocycl. Chem.* **2017**, *47*, 191–244.
- (a) Barlow, T. M. A.; Tourwé, D.; Ballet, S. *Eur. J. Org. Chem.* **2017**, 4678–4694. (b) Johansson, J. R.; Beke-Somfai, T.; Said Stålsmeden, A.; Kann, N. *Chem. Rev.* **2016**, *116*, 14726–14768. (c) Kelly, A. R.; Wei, J.; Kesavan, S.; Marié, J. C.; Windmon, N.; Young, D. W.; Marcaurelle, L. A. *Org. Lett.* **2009**, *11*, 2257–2260. (d) Boren, B. C.; Narayan, S.; Rasmussen, L. K.; Zhang, L.; Zhao, H.; Lin, Z.; Jia, G.; Fokin, V. V. *J. Am. Chem. Soc.* **2008**, *130*, 8923–8930.
- Nicolaou, K. C.; Boddy, C. N. C.; Li, H.; Koumbis, A. E.; Hughes, R.; Natarajan, S.; Jain, N. F.; Ramanjulu, J. M.; Bräse, S.; Solomon, M. E. *Chem. Eur. J.* **1999**, *9*, 2602–2621.
- (a) Chinchilla, R.; Najera, C. *Chem. Soc. Rev.* **2011**, *40*, 5084–5121. (b) Chinchilla, R.; Najera, C. *Chem. Rev.* **2007**, *107*, 874–922.
- Brucelle, F.; Renaud, P. *Org. Lett.* **2012**, *14*, 3048–3051.
- Initially we have used imidazole-1-sulfonyl azide-HCl as the diazo-transfer reagent for the synthesis of azido acid **5**, according to: (a) Goddard-Borger, E. D.; Stick, R. V. *Org. Lett.* **2007**, *9*, 3797–3800, however, currently the significantly safer to handle imidazole-1-sulfonyl azide-H₂SO₄ is preferred, according to: (b) Potter, G. T.; Jayson, G. C.; Miller, G. J.; Gardiner, J. M. *J. Org. Chem.* **2016**, *81*, 3443–3446.
- Rijkers, D. T. S.; Adams, H. P. H. M.; Hemker, H. C.; Tesser, G. I. *Tetrahedron* **1995**, *51*, 11235–11250.
- Schwab, P.; Grubbs, R. H.; Ziller, J. W. *J. Am. Chem. Soc.* **1996**, *118*, 100–110.
- Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. *Org. Lett.* **1999**, *1*, 953–956.
- For a comprehensive review, see: Gololobov, Y. G.; Kasukhin, L. F.; *Tetrahedron* **1992**, *48*, 1353–1406
- Garber, S. B.; Kingsbury, J. S.; Gray B. L.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2000**, *122*, 8168–8179.
- Karplus M. *J. Am. Chem. Soc.* **1963**, *85*, 2870–2871.
- (a) Meldal, M.; Tornøe C. W. *Chem. Rev.* **2008**, *108*, 2952–3015. (b) Hein, J. E.; Fokin, V. V. *Chem Soc Rev.* **2010**, *39*, 1302–1315. (c) Singh, M. S.; Chowdhury, S.; Koley, S. *Tetrahedron* **2016**, *72*, 5257–5283.
- (a) Park, S.; Kim, M.; Lee, D. *J. Am. Chem. Soc.* **2005**, *127*, 9410–9415. (b) Ostrowska, S.; Powala, B.; Jankowska-Wajda, M.; Zak, P.; Rogalski, s.; Wyrzykiewicz, B.; Pietraszuk, C. *J. Organomet. Chem.* **2015**, *783*, 135–140.
- Modelling has been performed with using the YASARA software (www.yasara.org).
- The crystal structure of balhimycin (a vancomycin-related glycopeptide antibiotic) in complex with Lys-D-Ala-D-Ala (Protein Data bank accession code: IGO6) was used, see: Lehmann, C.; Bunkóczi, G.; Vértessy, L.; Sheldrick, G. M. *J. Mol. Biol.* **2002**, *318*, 723–732.
- McPhail, D.; Cooper, A. *J. Chem. Soc. Faraday Trans.* **1997**, *93*, 2283–2289.
- Xie, J.; Okano, A.; Pierce J. G.; James, R. C.; Stamm, S.; Crane C. M.; Boger, D. L. *J. Am. Chem. Soc.* **2012**, *134*, 1284–1297.
- Wiegand, I.; Hilpert, K.; Hancock, R. E. W. *Nature Protocols* **2008**, *3*, 163–175.

Supplementary Material

Experimental procedures, ¹H and ¹³C NMR spectra, HPLC profiles, HRMS spectra and ITC binding curves.